Otsuka/Lundbeck's brexpiprazole data reassure
This article was originally published in Scrip
Executive Summary
Otsuka and Lundbeck have released promising new Phase III data for their novel anti-psychotic brexpiprazole just as the US FDA has accepted their NDA for review both as a treatment for schizophrenia and as an adjunctive therapy in major depressive disorder (MDD).